发明授权
US08343544B2 Oral sustained-release tablet 失效
口服缓释片

Oral sustained-release tablet
摘要:
(Object) An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels.(Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.
公开/授权文献
信息查询
0/0